The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk
暂无分享,去创建一个
B. Adams-Huet | P. Tebas | N. Maalouf | Irfan M. Farukhi | J. Poindexter | Geri R. Brown | R. Bedimo | R. Castanon | D. Turner | Teresa Moore | G. Brown
[1] R. Weber,et al. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Jacques P. Brown,et al. A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] P. Tebas,et al. Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease , 2016, AIDS.
[4] M. Yin,et al. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis , 2014, AIDS.
[5] Heinrich Resch,et al. Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] P. Tebas,et al. Hepatitis C Co‐infection and Severity of Liver Disease as Risk Factors for Osteoporotic Fractures Among HIV‐Infected Patients , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] D. Neau,et al. Chronic Viral Hepatitis Is Associated With Low Bone Mineral Density in HIV-Infected Patients, ANRS CO 3 Aquitaine Cohort , 2013, Journal of acquired immune deficiency syndromes.
[8] C. Sabin,et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. , 2013, The Journal of clinical endocrinology and metabolism.
[9] Jeannie S. Huang,et al. Fractures after antiretroviral initiation , 2012, AIDS.
[10] A. Localio,et al. Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection , 2012, Hepatology.
[11] P. Tebas,et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents , 2012, AIDS.
[12] S. Gange,et al. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis , 2012, AIDS.
[13] C. Larsen,et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study , 2012, AIDS.
[14] Richard D Moore,et al. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. , 2011, Journal of hepatology.
[15] P. Sax,et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.
[16] K. Buchacz,et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Joseph L. Goulet,et al. Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans , 2011, PloS one.
[18] Mary Young,et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study , 2010, AIDS.
[19] H. Stellbrink,et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] D. Cooper,et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] A. Localio,et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men , 2009, AIDS.
[22] T. Brown,et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. , 2008, The Journal of clinical endocrinology and metabolism.
[23] Mardge H. Cohen,et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women , 2007, Antiviral therapy.
[24] H. Sørensen,et al. Cause-Specific Excess Mortality in Siblings of Patients Co-Infected with HIV and Hepatitis C Virus , 2007, PloS one.
[25] H. Sørensen,et al. Mortality in siblings of patients coinfected with HIV and hepatitis C virus. , 2007, The Journal of infectious diseases.
[26] T. Brown,et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.
[27] R. Porcher,et al. Diagnosis of vertebral fractures by vertebral fracture assessment. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[28] I. Schiefke,et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. , 2005, World journal of gastroenterology.
[29] W. Leslie,et al. AGA technical review on osteoporosis in hepatic disorders. , 2003, Gastroenterology.
[30] J. Kalbfleisch,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.
[31] J. Kanis,et al. Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.
[32] K. Yarasheski,et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.